Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-708-6 | CAS number: 688-84-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- 2-ethylhexyl methacrylate
- EC Number:
- 211-708-6
- EC Name:
- 2-ethylhexyl methacrylate
- Cas Number:
- 688-84-6
- Molecular formula:
- C12H22O2
- IUPAC Name:
- 2-ethylhexyl methacrylate
- Test material form:
- liquid
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- other: Human lymphocytes
- Details on mammalian cell type (if applicable):
- One healthy, non-smoking human volunteer (male) was used in this study. The donor was not suspected of any virus infection nor had been exposed to high levels of radiation or hazardous chemicals. An appropriate volume of whole blood was drawn from the peripheral circulation on the day of culture (Trial 1) or one day prior to culture (Trial 2). Blood was stored refrigerated until use. Whole blood cultures were established in sterile disposable centrifuge tubes by placing 0.4 mL heparinised blood into 9.0 mL Hepes-buffered RPMI medium containing 20% (v/v) foetal calf serum and 50 µg/mL gentamycin. Phytohaemagglutinin (PHA, reagent grade) was included at a concentration of approximately 10 µg per mL of culture to stimulate the lymphocytes to divide. Blood cultures were incubated for approximately 48 hours at 37°C and rocked continuously.
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver post-mitochondrial fraction (S-9) from Aroclor 1254 induced animals
- Test concentrations with justification for top dose:
- Trial 1: 79.90, 114.1, 163.1, 232.9, 332.8, 475.4, 679.1, 970.2, 1386 and 1980 µg/ml
Trial 2: 17.18, 21.47, 26.84, 33.55, 41.94, 52.43, 65.54, 81.92, 102.4, 128.0, 160.0 and 200.0 µg/ml - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: acetone
- Justification for choice of solvent/vehicle: solubility
The highest dose level used, 1980 µg/mL was equivalent to a 10 mM concentration and exceeded the limit of solubility.
Controls
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 4-Nitroquinoline 1-oxide (-S9) and cyclophosphamide (+S9)
- Details on test system and experimental conditions:
- DURATION
- Fixation time (start of exposure up to fixation or harvest of cells): Treatment in the absence of S-9 was continuous for 20 or 44 hours (20+0, 44+0). Treatment in the presence of S-9 was for 3 hours only followed by a 17 or 41 hour recovery period (3+17, 3+41). The test article dose levels for chromosome analysis were selected by evaluating the effect of 2-ethylhexyl methacrylate on mitotic index. Following 20+0 hour treatments, -S-9 and 3+17 hour treatments, +S-9, chromosome aberrations were analyzed at three consecutive dose levels.
The effects of single concentrations only, (41.94 µg/mL, without and 1980 µg/mL with S-9) were investigated at the delayed (44+0, 3+41) sampling time.
SPINDLE INHIBITOR (cytogenetic assays): Approximately 1½ hours prior to harvest, colchicine was added to give a final concentration of approximately 1µg/mL to arrest dividing cells in metaphase.
STAIN (for cytogenetic assays):
After the slides had dried the cells were stained for 5 minutes in 4% (v/v) filtered Giemsa stain in pH 6.8 buffer. The slides were rinsed, dried and mounted with coverslips.
NUMBER OF CELLS EVALUATED:
Twenty-five cells from each of the selected NQO and CPA positive control cultures were analysed to ensure that the system was operating satisfactorily. Where possible 100, metaphases from each test concentration were analysed for chromosome aberrations.
DETERMINATION OF CYTOTOXICITY
Slides were examined, uncoded, for mitotic index (MI) or percentage of cells in mitosis. Slides from enough dose levels from each treatment regime were scored to determine if chemically induced mitotic inhibition had occurred. This is defined as a clear decrease in mitotic index compared with negative controls (based on at least 1000 cells counted), preferably dose-related.
OTHER EXAMINATIONS:
Only cells with 44-46 chromosomes were considered acceptable for analysis of structural aberrations. Any cell with more than 46 chromosomes, that is polyploid, endoreduplicated and hyperdiploid cells, observed during this search was noted and recorded separately. - Evaluation criteria:
- The test article was to be considered as positive in this assay if:
1) a statistically significant increase in the proportion of cells with structural aberrations (excluding gaps) occurred at one or more concentrations, and
2) the proportion of cells with structural aberrations at such doses exceeded the normal range.
A positive result only at the delayed harvest was to be taken as evidence of clastogenicity provided criteria 1 and 2 were met. Increases in numbers of cells with gaps or increases in the proportions of cells with structural aberrations, not exceeding the normal range or occurring only at very high or very toxic concentrations, were likely to be concluded as "equivocal". Full assessment of the biological importance of such increases is likely only to be possible with reference to data from other test systems. Cells with exchange aberrations or cells with greater than one aberration were to be considered of particular biological significance. - Statistics:
- Fisher's exact test
Results and discussion
Test results
- Species / strain:
- other: Human lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- The highest concentrations chosen for analysis, 65.54 µg/mL and 1980 µg/mL, induced approximately 67% and 54% mitotic inhibition (reduction in mitotic index) in the absence and presence of S-9 respectively.
The proportion of cells with structural aberrations in negative control cultures fell within historical solvent control ranges. Untreated cultures were not analysed. Cells receiving the positive controls were sampled 20 hours after the start of treatment; both compounds induced statistically significant increases in the proportion of cells with structural aberrations.
Treatment of cultures with 2-ethylhexyl methacrylate in the absence of S-9 resulted in frequencies of cells with aberrations which were similar to and not significantly different from those seen in concurrent negative control ranges. Numbers of cells with aberrations in all treated cultures fell within the historical negative control (normal) range at both sampling times.
Treatment of cultures with 2-ethylhexyl methacrylate in the presence of S-9 resulted in frequencies of cells with aberrations which were significantly higher than those in concurrent controls. Numbers of aberrant cells, however, exceeded the normal range in only a single replicate at the highest dose level at each sampling time. Insofar as increases at this concentration were very small and not reproduced in both replicates the observation was not considered biologically significant.
Any other information on results incl. tables
2-Ethylhexyl methacrylate: summary of the numbers and types of structural aberrations observed without S9
20+0 hours
Treatment (µg/mL) |
Rep |
Cells * |
g |
Chr del |
Chr exch |
Ctd del |
Ctd exch |
Other |
Abs +g |
Abs -g |
Solvent |
A |
100 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
B |
100 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Total |
200 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
|
41.94 |
A |
100 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
B |
100 |
1 |
1 |
0 |
5 |
0 |
0 |
7 |
6 |
|
Total |
200 |
2 |
1 |
0 |
5 |
0 |
0 |
8 |
6 |
|
52.43 |
A |
100 |
0 |
1 |
0 |
0 |
0 |
1 |
2 |
2 |
B |
100 |
2 |
1 |
0 |
0 |
0 |
0 |
3 |
1 |
|
Total |
200 |
2 |
2 |
0 |
0 |
0 |
1 |
5 |
3 |
|
65.54 |
A |
80 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
1 |
B |
80 |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
2 |
|
Total |
160 |
0 |
0 |
0 |
3 |
0 |
0 |
3 |
3 |
|
NQO, 2.5 |
A |
25 |
2 |
3 |
0 |
3 |
11 |
3 |
22 |
20 |
B |
25 |
0 |
1 |
0 |
1 |
3 |
2 |
7 |
7 |
|
Total |
50 |
2 |
4 |
0 |
4 |
14 |
5 |
29 |
27 |
* = Total cells examined for structural aberrations
44+0 hours
Treatment (µg/mL) |
Rep |
Cells * |
g |
Chr del |
Chr exch |
Ctd del |
Ctd exch |
Other |
Abs +g |
Abs -g |
Solvent |
A |
100 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
1 |
B |
100 |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
2 |
|
Total |
200 |
0 |
1 |
0 |
2 |
0 |
0 |
3 |
3 |
|
41.94 |
A |
100 |
2 |
1 |
0 |
2 |
0 |
0 |
5 |
3 |
B |
100 |
2 |
0 |
0 |
3 |
0 |
0 |
5 |
3 |
|
Total |
200 |
4 |
1 |
0 |
5 |
0 |
0 |
10 |
6 |
2-Ethylhexyl methacrylate: summary of the numbers and types of numerical aberrations observed without S9
20+0 hours, Donor sex: male
Treatment (µg/mL) |
Rep |
Cells ** |
H |
E |
P |
Tot abs |
% with num abs |
Solvent |
A |
102 |
0 |
0 |
2 |
2 |
2.0 |
B |
101 |
0 |
0 |
1 |
1 |
1.0 |
|
Total |
203 |
0 |
0 |
3 |
3 |
1.5 |
|
41.94 |
A |
101 |
0 |
0 |
1 |
1 |
1.0 |
B |
103 |
1 |
0 |
2 |
3 |
2.9 |
|
Total |
204 |
1 |
0 |
3 |
4 |
2.0 |
|
52.43 |
A |
100 |
0 |
0 |
0 |
0 |
0 |
B |
102 |
0 |
0 |
2 |
2 |
2.0 |
|
Total |
202 |
0 |
0 |
2 |
2 |
1.0 |
|
65.54 |
A |
80 |
0 |
0 |
0 |
0 |
0 |
B |
81 |
1 |
0 |
0 |
1 |
1.2 |
|
Total |
161 |
1 |
0 |
0 |
1 |
0.6 |
|
NQO, 2.5 |
A |
25 |
0 |
0 |
0 |
0 |
0 |
B |
25 |
0 |
0 |
0 |
0 |
0 |
|
Total |
50 |
0 |
0 |
0 |
0 |
0 |
44+0 hours, Donor sex: male
Treatment (µg/mL) |
Rep |
Cells ** |
H |
E |
P |
Tot abs |
% with num abs |
Solvent |
A |
102 |
0 |
0 |
2 |
2 |
2.0 |
B |
103 |
1 |
0 |
2 |
3 |
2.9 |
|
Total |
205 |
1 |
0 |
4 |
5 |
2.4 |
|
41.94 |
A |
103 |
0 |
0 |
3 |
3 |
2.9 |
B |
101 |
0 |
0 |
1 |
1 |
1.0 |
|
Total |
204 |
0 |
0 |
4 |
4 |
2.0 |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results: negative
2-Ethylhexyl methacrylate did not induce chromosome aberrations in cultured human peripheral blood lymphocytes when tested to its limit of toxicity in both the absence and presence of S-9 - Executive summary:
In an OECD guideline 473and GLP in vitro cytogenetics assay, 2-Ethylhexyl methacrylate was tested using duplicate human lymphocyte cultures from a male human donor. Treatments covering a broad range of doses, separated by narrow intervals, were performed both in the absence and presence of metabolic activation by a rat liver post-mitochondrial fraction (S-9) from Aroclor 1254 induced animals. The highest dose level used, 1980 µg/mL was equivalent to a 10 mM concentration and exceeded the limit of solubility. Treatment in the absence of S-9 was continuous for 20 or 44 hours (20+0, 44+0). Treatment in the presence of S-9 was for 3 hours only followed by a 17 or 41 hour recovery period (3+17, 3+41). The test article dose levels for chromosome analysis were selected by evaluating the effect of 2-ethylhexyl methacrylate on mitotic index. Following 20+0 hour treatments, -S-9 and 3+17 hour treatments, +S-9, chromosome aberrations were analysed at three consecutive dose levels. The highest concentrations chosen for analysis, 65.54 µg/mL and 1980 µg/mL, induced approximately 67% and 54% mitotic inhibition (reduction in mitotic index) in the absence and presence of S-9 respectively. The effects of single concentrations only, (41.94 µg/mL, without and 1980 µg/mL with S-9) were investigated at the delayed (44+0, 3+41) sampling time.
Appropriate negative (solvent) control cultures and untreated cultures were included in the test system under each treatment condition. The proportion of cells with structural aberrations in negative control cultures fell within historical solvent control ranges. Untreated cultures were not analysed. 4-Nitroquinoline 1-oxide and cyclophosphamide were employed as positive control chemicals in the absence and presence of liver S-9 respectively. Cells receiving these were sampled 20 hours after the start of treatment; both compounds induced statistically significant increases in the proportion of cells with structural aberrations.
Treatment of cultures with 2-ethylhexyl methacrylate in the absence of S-9 resulted in frequencies of cells with aberrations which were similar to and not significantly different from those seen in concurrent negative control ranges. Numbers of cells with aberrations in all treated cultures fell within the historical negative control (normal) range at both sampling times.
Treatment of cultures with 2-ethylhexyl methacrylate in the presence of S-9 resulted in frequencies of cells with aberrations which were significantly higher than those in concurrent controls. Numbers of aberrant cells, however, exceeded the normal range in only a single replicate at the highest dose level at each sampling time. Insofar as increases at this concentration were very small and not reproduced in both replicates the observation was not considered biologically significant.
It is concluded that 2-Ethylhexyl methacrylate did not induce chromosome aberrations in cultured human peripheral blood lymphocytes when tested to its limit of toxicity in both the absence and presence of S-9.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.